S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in

Coherus BioSciences Stock Forecast, Price & News

-0.01 (-0.06 %)
(As of 02/24/2021 12:00 AM ET)
Today's Range
Now: $16.23
50-Day Range
MA: $18.10
52-Week Range
Now: $16.23
Volume851,455 shs
Average Volume1.44 million shs
Market Capitalization$1.17 billion
P/E Ratio7.96
Dividend YieldN/A
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Coherus BioSciences logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:CHRS
Year FoundedN/A



Sales & Book Value

Annual Sales$356.07 million
Cash Flow$1.21 per share
Book Value$1.50 per share


Net Income$89.83 million


Market Cap$1.17 billion
Next Earnings Date5/4/2021 (Estimated)


Overall MarketRank

1.43 out of 5 stars

Medical Sector

508th out of 1,958 stocks

Biological Products, Except Diagnostic Industry

71st out of 177 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
-0.01 (-0.06 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Coherus BioSciences (NASDAQ:CHRS) Frequently Asked Questions

Is Coherus BioSciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Coherus BioSciences stock.
View analyst ratings for Coherus BioSciences
or view top-rated stocks.

What stocks does MarketBeat like better than Coherus BioSciences?

Wall Street analysts have given Coherus BioSciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Coherus BioSciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Coherus BioSciences' next earnings date?

Coherus BioSciences is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Coherus BioSciences

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its quarterly earnings data on Wednesday, February, 24th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.25 by $0.13. Coherus BioSciences had a trailing twelve-month return on equity of 90.98% and a net margin of 33.06%.
View Coherus BioSciences' earnings history

How has Coherus BioSciences' stock price been impacted by Coronavirus?

Coherus BioSciences' stock was trading at $15.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CHRS shares have increased by 2.3% and is now trading at $16.23.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CHRS?

6 analysts have issued 12-month target prices for Coherus BioSciences' shares. Their forecasts range from $20.00 to $36.00. On average, they expect Coherus BioSciences' stock price to reach $28.50 in the next twelve months. This suggests a possible upside of 75.6% from the stock's current price.
View analysts' price targets for Coherus BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Coherus BioSciences' key executives?

Coherus BioSciences' management team includes the following people:
  • Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 66, Pay $1.81M)
  • Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 55, Pay $836.38k)
  • Mr. Vincent R. Anicetti, Chief Operating Officer (Age 66, Pay $817.63k)
  • Mr. Vladimir Vexler, Chief Scientific Officer (Age 63, Pay $764.02k)
  • Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Scientific Advisory Board (Age 69, Pay $86.25k)
  • Mr. McDavid Stilwell, Exec. VP of Corp. Devel., Investor Relations & Financial Strategy
  • Mr. Thomas F. Fitzpatrick, Chief Legal Officer
  • Mr. Chris Thompson, Exec. VP of Sales
  • Ms. Rebecca Sunshine, Exec. VP of HR (Age 58)
  • Dr. Barbara K. Finck, Chief Clinical Advisor, Acting Chief Medical Officer & Member of Scientific Advisory Board (Age 74)

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences CEO Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among Coherus BioSciences' employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Coherus BioSciences' key competitors?

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (14.61%), JPMorgan Chase & Co. (6.88%), Alliancebernstein L.P. (6.53%), Aristotle Capital Boston LLC (2.47%), Vaughan Nelson Investment Management L.P. (2.26%) and Peregrine Capital Management LLC (1.25%). Company insiders that own Coherus BioSciences stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends for Coherus BioSciences

Which major investors are selling Coherus BioSciences stock?

CHRS stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Brown Advisory Inc., Lord Abbett & CO. LLC, Nuveen Asset Management LLC, Wells Fargo & Company MN, Rice Hall James & Associates LLC, SG Americas Securities LLC, and Principal Financial Group Inc.. Company insiders that have sold Coherus BioSciences company stock in the last year include Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Vincent R Anicetti, and Vladimir Vexler.
View insider buying and selling activity for Coherus BioSciences
or view top insider-selling stocks.

Which major investors are buying Coherus BioSciences stock?

CHRS stock was bought by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Aristotle Capital Boston LLC, HealthInvest Partners AB, Peregrine Capital Management LLC, Morgan Stanley, BlackRock Inc., Barclays PLC, and JPMorgan Chase & Co..
View insider buying and selling activity for Coherus BioSciences
or or view top insider-buying stocks.

How do I buy shares of Coherus BioSciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $16.23.

How much money does Coherus BioSciences make?

Coherus BioSciences has a market capitalization of $1.17 billion and generates $356.07 million in revenue each year. The biotechnology company earns $89.83 million in net income (profit) each year or $1.23 on an earnings per share basis.

How many employees does Coherus BioSciences have?

Coherus BioSciences employs 306 workers across the globe.

What is Coherus BioSciences' official website?

The official website for Coherus BioSciences is www.coherus.com.

Where are Coherus BioSciences' headquarters?

Coherus BioSciences is headquartered at 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065.

How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]

This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.